Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):558–564. doi: 10.1038/sj.bjc.6690088

Syndecan-1 expression has prognostic significance in head and neck carcinoma

A Anttonen 1, M Kajanti 1, P Heikkilä 2, M Jalkanen 3, H Joensuu 1
PMCID: PMC2362450  PMID: 10027330

Abstract

The syndecans are a family of cell-surface heparan sulphate proteoglycans that regulate cell behaviour by binding extracellular matrix molecules such as growth factors. The syndecan family has four members, of which syndecan-1 is the most studied and best characterized. We have studied the prognostic significance of syndecan-1 expression in squamous cell carcinoma (SCC) of the head and neck treated with surgery and post-operative radiotherapy. Paraffin-embedded tissue samples taken from 175 patients with primary SCC, followed up from 2 to 15 years after surgery, were studied for expression of syndecan-1 by immunohistochemistry. A low number (≤50%, the median value) of syndecan-1-positive tumour cells was associated with low histological grade of differentiation (P < 0.0001), a large primary tumour size (T1–2 vs T3–4, P = 0.02), positive nodal status (N0 vs N1–3, P = 0.0006), and high clinical stage (stage I or II vs III or IV, P < 0.0001). Low syndecan-1 expression was also associated with unfavourable overall survival in a univariate analysis (P = 0.001). In a multivariate survival analysis, the clinical stage and syndecan-1 expression were the only independent prognostic factors. We conclude that syndecan-1 is a novel prognostic factor in SCC of the head and neck treated with surgery and post-operative radiotherapy. © 1999 Cancer Research Campaign

Keywords: proteoglycan, squamous cell carcinoma, head and neck cancer, prognosis, syndecan

Full Text

The Full Text of this article is available as a PDF (291.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benasso M., Bonelli L., Numico G., Corvò R., Sanguineti G., Rosso R., Vitale V., Merlano M. Treatment with cisplatin and fluorouracil alternating with radiation favourably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients. Ann Oncol. 1997 Aug;8(8):773–779. doi: 10.1023/a:1008244110004. [DOI] [PubMed] [Google Scholar]
  2. Bernfield M., Kokenyesi R., Kato M., Hinkes M. T., Spring J., Gallo R. L., Lose E. J. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992;8:365–393. doi: 10.1146/annurev.cb.08.110192.002053. [DOI] [PubMed] [Google Scholar]
  3. Cook D. M., Hinkes M. T., Bernfield M., Rauscher F. J., 3rd Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1. Oncogene. 1996 Oct 17;13(8):1789–1799. [PubMed] [Google Scholar]
  4. El-Sayed S., Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol. 1996 Mar;14(3):838–847. doi: 10.1200/JCO.1996.14.3.838. [DOI] [PubMed] [Google Scholar]
  5. Elenius K., Mättä A., Salmivirta M., Jalkanen M. Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem. 1992 Mar 25;267(9):6435–6441. [PubMed] [Google Scholar]
  6. Elenius K., Vainio S., Laato M., Salmivirta M., Thesleff I., Jalkanen M. Induced expression of syndecan in healing wounds. J Cell Biol. 1991 Aug;114(3):585–595. doi: 10.1083/jcb.114.3.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hayashi K., Hayashi M., Jalkanen M., Firestone J. H., Trelstad R. L., Bernfield M. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study. J Histochem Cytochem. 1987 Oct;35(10):1079–1088. doi: 10.1177/35.10.2957423. [DOI] [PubMed] [Google Scholar]
  8. Horiot J. C., Le Fur R., N'Guyen T., Chenal C., Schraub S., Alfonsi S., Gardani G., Van Den Bogaert W., Danczak S., Bolla M. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992 Dec;25(4):231–241. doi: 10.1016/0167-8140(92)90242-m. [DOI] [PubMed] [Google Scholar]
  9. Inki P., Joensuu H., Grénman R., Klemi P., Jalkanen M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br J Cancer. 1994 Aug;70(2):319–323. doi: 10.1038/bjc.1994.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Inki P., Kujari H., Jalkanen M. Syndecan in carcinomas produced from transformed epithelial cells in nude mice. Lab Invest. 1992 Mar;66(3):314–323. [PubMed] [Google Scholar]
  11. Inki P., Stenbäck F., Talve L., Jalkanen M. Immunohistochemical localization of syndecan in mouse skin tumors induced by UV irradiation. Loss of expression associated with malignant transformation. Am J Pathol. 1991 Dec;139(6):1333–1340. [PMC free article] [PubMed] [Google Scholar]
  12. Koda J. E., Rapraeger A., Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. Cell surface proteoglycan as a receptor for interstitial collagens. J Biol Chem. 1985 Jul 5;260(13):8157–8162. [PubMed] [Google Scholar]
  13. Kojima T., Shworak N. W., Rosenberg R. D. Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J Biol Chem. 1992 Mar 5;267(7):4870–4877. [PubMed] [Google Scholar]
  14. Liotta L. A., Rao C. N., Wewer U. M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem. 1986;55:1037–1057. doi: 10.1146/annurev.bi.55.070186.005133. [DOI] [PubMed] [Google Scholar]
  15. Pera E., Moreno A., Galindo L. Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases. Cancer. 1986 Aug 15;58(4):928–934. doi: 10.1002/1097-0142(19860815)58:4<928::aid-cncr2820580421>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  16. Pulkkinen J. O., Penttinen M., Jalkanen M., Klemi P., Grénman R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol. 1997 Mar;117(2):312–315. doi: 10.3109/00016489709117794. [DOI] [PubMed] [Google Scholar]
  17. Rapraeger A. C., Bernfield M. Heparan sulfate proteoglycans from mouse mammary epithelial cells. A putative membrane proteoglycan associates quantitatively with lipid vesicles. J Biol Chem. 1983 Mar 25;258(6):3632–3636. [PubMed] [Google Scholar]
  18. Salmivirta M., Elenius K., Vainio S., Hofer U., Chiquet-Ehrismann R., Thesleff I., Jalkanen M. Syndecan from embryonic tooth mesenchyme binds tenascin. J Biol Chem. 1991 Apr 25;266(12):7733–7739. [PubMed] [Google Scholar]
  19. Salmivirta M., Mali M., Heino J., Hermonen J., Jalkanen M. A novel laminin-binding form of syndecan-1 (cell surface proteoglycan) produced by syndecan-1 cDNA-transfected NIH-3T3 cells. Exp Cell Res. 1994 Nov;215(1):180–188. doi: 10.1006/excr.1994.1330. [DOI] [PubMed] [Google Scholar]
  20. Salmivirta M., Rauvala H., Elenius K., Jalkanen M. Neurite growth-promoting protein (amphoterin, p30) binds syndecan. Exp Cell Res. 1992 Jun;200(2):444–451. doi: 10.1016/0014-4827(92)90194-d. [DOI] [PubMed] [Google Scholar]
  21. Saunders S., Bernfield M. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J Cell Biol. 1988 Feb;106(2):423–430. doi: 10.1083/jcb.106.2.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sun X., Mosher D. F., Rapraeger A. Heparan sulfate-mediated binding of epithelial cell surface proteoglycan to thrombospondin. J Biol Chem. 1989 Feb 15;264(5):2885–2889. [PubMed] [Google Scholar]
  23. Thesleff I., Jalkanen M., Vainio S., Bernfield M. Cell surface proteoglycan expression correlates with epithelial-mesenchymal interaction during tooth morphogenesis. Dev Biol. 1988 Oct;129(2):565–572. doi: 10.1016/0012-1606(88)90401-0. [DOI] [PubMed] [Google Scholar]
  24. Vainio S., Lehtonen E., Jalkanen M., Bernfield M., Saxén L. Epithelial-mesenchymal interactions regulate the stage-specific expression of a cell surface proteoglycan, syndecan, in the developing kidney. Dev Biol. 1989 Aug;134(2):382–391. doi: 10.1016/0012-1606(89)90110-3. [DOI] [PubMed] [Google Scholar]
  25. Wiernik G., Millard P. R., Haybittle J. L. The predictive value of histological classification into degrees of differentiation of squamous cell carcinoma of the larynx and hypopharynx compared with the survival of patients. Histopathology. 1991 Nov;19(5):411–417. doi: 10.1111/j.1365-2559.1991.tb00230.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES